Ferentis is a research-intensive biotechnology company involved in the development, production and commercialisation of biomimetic peptides and peptide-based scaffolds for tissue engineering and regenerative medicine applications.
Ferentis was established in Vilnius, Lithuania, by a group of scientists and entrepreneurs from Canada, Lithuania, Sweden and India.
Our products are based on state-of-the-art research in the fields of biomaterials, enhanced cell regeneration, medicinal chemistry, peptidomimetics and surface nano technology. Our founders have extensive experience leading multi-disciplinary research groups and successfully translating their research discoveries into clinical studies.
The mission of Ferentis is to develop “smart” biomaterials that can promote regeneration of tissue cells within the patient without the need for long-term immunosuppressive drugs. Ferentis’ range of products are designed to mimic the biologically-active extracellular matrix of the body that serves as scaffolding and glue to keep the body intact, as well as providing instructions for the repair and regeneration of tissues and organs.
Ferentis’ primary commercial focus is hydrogel products and kits for in vitro cell and tissue culture applications. We will also assist our clients in custom-design of biomimetic materials as templates for stimulating regeneration of target tissues and organs for potential clinical application.
Our target customers are scientific institutions, biopharma and the consumer products industry. Our products provide innovative solutions for professionals who are working in the fields of cell research, regenerative medicine, testing and production of drugs, cosmetic and other bioactive products.
